Comparison of Anti-Il-17a, IL-17F and TNF-α Antibodies on Host Resistance to Acute Mycobacterium Tuberculosis Infection in Mice

Michael Kammueller,Franco DiPadova,Salahdine Chibout,Timothy Wright,Marie-Laure Bourigault,Noria Segueni,Stephanie Rose,Bernhard Ryffel,Valerie Quesniaux
DOI: https://doi.org/10.1016/j.jdermsci.2016.08.198
IF: 5.408
2016-01-01
Journal of Dermatological Science
Abstract:Antibodies targeting IL-17A or IL-17RA are in clinical trials for the treatment of several autoimmune diseases. These therapies, by blocking critical mediators of innate and adaptive immunity, may carry the risk of an increased susceptibility to infections. While M. tuberculosis infections can be an important complication of anti-TNFα therapies, the role of the Th17/IL-17 pathway in host resistance to this intracellular pathogen is less clear. The effect of neutralizing IL-17A or IL-17F during acute M. tuberculosis infection was evaluated in a 4-week aerosol mouse model. M. tuberculosis infected C57BL/6 mice were treated once per week i.p. with 0.5 mg of anti-mouse IL-17A or IL-17F antibodies, 0.25 mg of anti-mouse TNFα antibody, and respective isotype control antibodies, starting 1 day before the infection. Disease symptoms, lung and spleen weight, pulmonary bacterial burden and histopathology were assessed at day 28. IL-17A or IL-17F blockade like the isotype controls did not alter body, lung, and spleen weights, pulmonary bacterial burden and histopathology. In mice treated with a neutralizing anti-TNFα antibody, body weight was decreased, while lung and spleen inflammation and pulmonary bacterial burden were increased. Changes were associated with a worsening of the microscopic observations in the lung with the anti-TNFα antibody. These results confirm the importance of TNFα in host resistance to M. tuberculosis infection, and highlight that anti- IL-17A or anti-IL-17F treatment for 4 weeks in vivo do not impair immunity in an acute mouse M. tuberculosis infection model.
What problem does this paper attempt to address?